The Role of Immunotherapy in the Treatment of Advanced Cervical Cancer: Current Status and Future Perspectives

被引：24

作者：

Walsh, Robert J. ^{[1
]}

Tan, David S. P. ^{[1
,2
]}

机构：

[1] Natl Univ Canc Inst, Singapore 119074, Singapore

[2] Natl Univ Singapore, Canc Sci Inst, Singapore 117599, Singapore

来源：

JOURNAL OF CLINICAL MEDICINE | 2021年 / 10卷 / 19期

基金：

英国医学研究理事会;

关键词：

cervical cancer; immunotherapy; immune checkpoint inhibitor; SQUAMOUS-CELL CARCINOMA; NIVOLUMAB PLUS IPILIMUMAB; PHASE-II; T-CELLS; MICROSATELLITE INSTABILITY; INTRAEPITHELIAL NEOPLASIA; ACQUIRED-RESISTANCE; EXPRESSION; CHEMOTHERAPY; PD-L1;

D O I：

10.3390/jcm10194523

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Cervical cancer remains one of the most common cancers in women around the world however therapeutic options in the advanced and recurrent setting are limited. Immune checkpoint inhibitors (ICI) have been considered an attractive option given the viral etiology of cervical cancer although the majority of patients do not benefit from their use. This review summarises current knowledge and use of immune checkpoint blockade in cervical cancer as well as discussing the challenges faced in their clinical application, namely, the role of biomarker-driven ICI use, potential mechanisms of resistance, strategies to overcome such resistance and additional immunotherapy options beyond ICI.

引用

页数：14

共 89 条

[71] TALEN based HPV-E7 editing triggers necrotic cell death in cervical cancer cells [J].

Shankar, Sumitra ;

Prasad, Deepti ;

Sanawar, Rahul ;

Das, Ani V. ;

Pillai, M. Radhakrishna .

SCIENTIFIC REPORTS, 2017, 7

[72] Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC [J].

Socinski, M. A. ;

Jotte, R. M. ;

Cappuzzo, F. ;

Orlandi, F. ;

Stroyakovskiy, D. ;

Nogami, N. ;

Rodriguez-Abreu, D. ;

Moro-Sibilot, D. ;

Thomas, C. A. ;

Barlesi, F. ;

Finley, G. ;

Kelsch, C. ;

Lee, A. ;

Coleman, S. ;

Deng, Y. ;

Shen, Y. ;

Kowanetz, M. ;

Lopez-Chavez, A. ;

Sandler, A. ;

Reck, M. ;

Ahualli, A. ;

Jarchum, G. ;

Kaen, D. L. ;

Kahl, S. ;

Kotliar, M. ;

Kowalyszyn, R. D. ;

Lerzo, G. ;

Magri, I ;

Martin, C. ;

Pastor, A. ;

Picon, P. ;

Streich, G. ;

Varela, M. ;

Blinman, P. ;

Boyer, M. ;

Crombie, C. ;

Gauden, S. ;

Gill, S. ;

Hughes, B. ;

John, T. ;

Joshi, A. ;

Kosmider, S. ;

Lewis, C. ;

Millward, M. ;

Nordman, I ;

Nott, L. ;

O'Byrne, K. ;

Parnis, F. ;

Potasz, N. ;

Richardson, G. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (24) :2288-2301

[73] De-novo and acquired resistance to immune checkpoint targeting [J].

Syn, Nicholas L. ;

Teng, Michele W. L. ;

Mok, Tony S. K. ;

Soo, Ross A. .

LANCET ONCOLOGY, 2017, 18 (12) :E731-E741

[74] The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications [J].

Tamura, Ryota ;

Tanaka, Toshihide ;

Akasaki, Yasuharu ;

Murayama, Yuichi ;

Yoshida, Kazunari ;

Sasaki, Hikaru .

MEDICAL ONCOLOGY, 2020, 37 (01)

[75] Neuroendocrine carcinoma of the cervix: a systematic review of the literature [J].

Tempfer, Clemens B. ;

Tischoff, Iris ;

Dogan, Askin ;

Hilal, Ziad ;

Schultheis, Beate ;

Kern, Peter ;

Rezniczek, Guenther A. .

BMC CANCER, 2018, 18

[76] VP4-2021: EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9: Interim analysis of phase III trial of cemiplimab vs. investigator's choice (IC) chemotherapy (chemo) in recurrent/metastatic (R/M) cervical carcinoma [J].

Tewari, K. S. ;

Monk, B. J. ;

Vergote, I. ;

Miller, A. ;

de Melo, A. C. ;

Kim, H. S. ;

Kim, Y. M. ;

Lisyanskaya, A. ;

Samouelian, V. ;

Lorusso, D. ;

Damian, F. ;

Chang, C-L. ;

Gotovkin, E. A. ;

Takahashi, S. ;

Ramone, D. ;

Pikiel, J. ;

Li, J. ;

Mathias, M. ;

Fury, M. G. ;

Oaknin, A. .

ANNALS OF ONCOLOGY, 2021, 32 (07) :940-941

[77] Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240) [J].

Tewari, Krishnansu S. ;

Sill, Michael W. ;

Penson, Richard T. ;

Huang, Helen ;

Ramondetta, Lois M. ;

Landrum, Lisa M. ;

Oaknin, Ana ;

Reid, Thomas J. ;

Leitao, Mario M. ;

Michael, Helen E. ;

DiSaia, Philip J. ;

Copeland, Larry J. ;

Creasman, William T. ;

Stehman, Frederick B. ;

Brady, Mark F. ;

Burger, Robert A. ;

Thigpen, J. Tate ;

Birrer, Michael J. ;

Waggoner, Steven E. ;

Moore, David H. ;

Look, Katherine Y. ;

Koh, Wui-Jin ;

Monk, Bradley J. .

LANCET, 2017, 390 (10103) :1654-1663

[78] Tumor-infiltrating CD14-positive myeloid cells and CD8-positive T-cells prolong survival in patients with cervical carcinoma [J].

van Steenwijk, P. J. de Vos ;

Ramwadhdoebe, T. H. ;

Goedemans, R. ;

Doorduijn, E. M. ;

van Ham, J. J. ;

Gorter, A. ;

van Hall, T. ;

Kuijjer, M. L. ;

van Poelgeest, M. I. E. ;

van der Burg, S. H. ;

Jordanova, E. S. .

INTERNATIONAL JOURNAL OF CANCER, 2013, 133 (12) :2884-2894

[79] Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients [J].

Vanderwalde, Ari ;

Spetzler, David ;

Xiao, Nianqing ;

Gatalica, Zoran ;

Marshall, John .

CANCER MEDICINE, 2018, 7 (03) :746-756

[80] VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors [J].

Voron, Thibault ;

Colussi, Orianne ;

Marcheteau, Elie ;

Pernot, Simon ;

Nizard, Mevyn ;

Pointet, Anne-Laure ;

Latreche, Sabrina ;

Bergaya, Sonia ;

Benhamouda, Nadine ;

Tanchot, Corinne ;

Stockmann, Christian ;

Combe, Pierre ;

Berger, Anne ;

Zinzindohoue, Franck ;

Yagita, Hideo ;

Tartour, Eric ;

Taieb, Julien ;

Terme, Magali .

JOURNAL OF EXPERIMENTAL MEDICINE, 2015, 212 (02) :139-148

← 1 2 3 4 5 6 7 8 9 →